Latest Conference Articles

A conversation with Lauren Angelo, PharmD, MBA, associate dean of academic affairs and associate professor of pharmacy practice at Rosalind Franklin University of Medicine and Science College of Pharmacy.

The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.

AJ Loiacono, co-founder and CEO of Capital RX, discusses how the National Average Drug Acquisition Cost provides accuracy and transparency for stakeholders across the drug supply chain.

David Ha, PharmD, BCIDP, discusses why pharmacies should begin offering more vaccines and how they can better market their services to the community.

The first of a 2-part presentation focused on vaccines for COVID-19, flu, RSV, and pneumococcal disease.

The cost effectiveness of biosimilar denosumab for postmenopausal osteoporosis varies significantly based on factors like adherence, subsequent therapies, and treatment duration.

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

Research presented at AMCP Nexus 2024 underscored and explored the need for treatments that can prevent or mitigate flare-ups in patients with AD.

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

Posters presented at IDWeek 2024 provided new insights into the impact of COVID-19 infection and vaccination on women’s health.

Analyzing copayments and coverage plans for popular weight-loss drugs in the US, researchers addressed the cost-effectiveness of GLP-1 medications for treating obesity.

Three posters showcased at IDWeek 2024 focused on enhancing access to HIV prevention and treatment, as well as increasing uptake of pre-exposure prophylaxis (PrEP) among women.

Multimodal analgesia provides more effective pain management—and leads to a decrease in opioid use.

Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.

Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.

Vaccination against HPV can prevent thousands of cases of cancer each year.

Researchers explored the efficacy of Pfizer-BioNTech’s updated COVID-19 vaccine for the 2023-2024 period and its efficacy in improving various patient outcomes.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

In posters presented at the American College of Clinical Pharmacy 2024 Annual Meeting, researchers explored the implementation of collaborative care programs within various health systems.

Cases of meningococcal disease currently exceed prepandemic levels.

Findings from a collection of posters at ACCP underscore the critical role of community pharmacies in promoting health equity and providing high-quality, patient-centered care.

Dozens of presentations at IDWeek 2024 focused on available immunizations, such as those for COVID-19, respiratory syncytial virus, and flu.

Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.

Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.